Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
ALNY filed a patent for "rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)" on Mon, March 4, 2024. The patent was officially published on Thu, February 27, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
